Anadys' hepatitis C drug shows promise in midstage trial

12/17/2009 | Reuters

An experimental hepatitis C drug from Anadys Pharmaceuticals helped reduce the virus to an undetectable level in 56% of midstage-trial patients, compared with 20% of the placebo group, after four weeks of treatment. ANA598 was combined with pegylated interferon and ribavirin, a standard therapy.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC